The present invention comprises compounds of Formula I.
wherein:
R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, and R
9
are defined in the specification.
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim
1.
[EN] METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T<br/>[FR] MODULATEURS QUINOLINYLE À LIAISON MÉTHYLÈNE DE ROR-GAMMA-T
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2015057205A1
公开(公告)日:2015-04-23
The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
The present invention provides novel benzenediols and benzedioxins which selectively inhibit thromboxane A.sub.2 synthetase and as such represent useful and potent pharmacological agents.
Aroylcrownethers are complexing agents for metals, dispersing agents for carbon black and preferred ones are antiviral agents. Examplary is 4'-benzoylbenzo-18-crown-6 of the formula ##STR1##
Aroylcrownethers are complexing agents for metals, dispersing agents for carbon black and preferred ones are antiviral agents. Examplary is 4'-benzoylbenzo-18-crown-6 of the formula ##STR1##